Qiagen N.V. logo QGEN - Qiagen N.V.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 14
HOLD 16
SELL 0
STRONG
SELL 0
| PRICE TARGET: $43.01 DETAILS
HIGH: $48.00
LOW: $38.60
MEDIAN: $43.00
CONSENSUS: $43.01
DOWNSIDE: 5.60%

Stock News

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis prevention, screening and care. An estimated 10.7 million people worldwide developed tuberculosis in 2024 and nearly 1.2 million died from the d.

Oct 13, 2026 12:05 PM • businesswire.com
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery Platform, which extends these capabilities int.

Oct 06, 2026 12:05 PM • businesswire.com
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria and antibiotic resistance markers in about one hour, complementing the recently FDA-cleared QIAstat-Dx panel for gram-positive bacteria and fungi.

Sep 27, 2026 09:30 PM • businesswire.com
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample preparation system designed to give research laboratories a time-saving and cost-efficient alternative to processing samples by hand. QIAmini is designed primarily for academic laboratories and other research customers processing smaller sample batches that do not require larger automated systems. QIAGEN estimates the ad.

Sep 24, 2026 12:05 PM • businesswire.com
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Shareholders will be asked to vote on the appointment of Jonathan M. Pratt to the QIAGEN Managing Board after he joined QIAGEN as Chief Executive Officer on September 1, 2026. Subject to shareholder approval, Jon Pratt would join Roland Sackers, Chief Financial Officer, as the two me.

Sep 18, 2026 12:05 PM • businesswire.com
Qiagen (NYSE:QGEN) & BioLife Solutions (NASDAQ:BLFS) Critical Contrast

Qiagen (NYSE:QGEN) & BioLife Solutions (NASDAQ:BLFS) Critical Contrast

BioLife Solutions (NASDAQ: BLFS - Get Free Report) and Qiagen (NYSE: QGEN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Institutional and Insider Ownership 93.2% of BioLife Solutions shares

Aug 30, 2026 10:59 PM • defenseworld.net
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.

Aug 28, 2026 10:38 AM • prnewswire.com
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction

QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and.

Aug 27, 2026 12:05 PM • businesswire.com
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer

QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corpor.

Aug 24, 2026 05:47 AM • businesswire.com

Price Targets